Phenyl aminosalicylate

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Phenyl aminosalicylate
Accession Number
DB06807
Type
Small Molecule
Groups
Approved
Description
Not Available
Structure
Thumb
Synonyms
  • Fenamisal
  • Fenamisalum
  • p-Aminosalol
  • Phenyl 4-aminosalicylate
  • Phenyl PAS
External IDs
NSC-40144
Categories
UNII
52936SIP7V
CAS number
133-11-9
Weight
Average: 229.235
Monoisotopic: 229.073893218
Chemical Formula
C13H11NO3
InChI Key
DNVVZWSVACQWJE-UHFFFAOYSA-N
InChI
InChI=1S/C13H11NO3/c14-9-6-7-11(12(15)8-9)13(16)17-10-4-2-1-3-5-10/h1-8,15H,14H2
IUPAC Name
phenyl 4-amino-2-hydroxybenzoate
SMILES
NC1=CC(O)=C(C=C1)C(=O)OC1=CC=CC=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Phenyl aminosalicylate.Approved
AcarbosePhenyl aminosalicylate may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcenocoumarolPhenyl aminosalicylate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Acetazolamide.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Phenyl aminosalicylate.Approved, Vet Approved
AlbiglutidePhenyl aminosalicylate may increase the hypoglycemic activities of Albiglutide.Approved
AlclometasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Aldosterone.Experimental, Investigational
AlogliptinPhenyl aminosalicylate may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Aloxiprin.Experimental
AlprostadilThe risk or severity of adverse effects can be increased when Alprostadil is combined with Phenyl aminosalicylate.Approved, Investigational
AlteplaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Alteplase.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Amcinonide.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
Ammonium chlorideThe serum concentration of Phenyl aminosalicylate can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
AnagrelideThe risk or severity of adverse effects can be increased when Anagrelide is combined with Phenyl aminosalicylate.Approved
AncrodPhenyl aminosalicylate may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Phenyl aminosalicylate.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with anecortave acetate.Investigational
AnistreplaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Anistreplase.Approved
Antithrombin III humanPhenyl aminosalicylate may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanPhenyl aminosalicylate may increase the anticoagulant activities of Apixaban.Approved
ArdeparinPhenyl aminosalicylate may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Phenyl aminosalicylate.Approved, Investigational
AstaxanthinThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Astaxanthin.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Atamestane.Investigational
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Phenyl aminosalicylate.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Phenyl aminosalicylate.Investigational
BalsalazideBalsalazide may increase the anticoagulant activities of Phenyl aminosalicylate.Approved, Investigational
BatroxobinThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Batroxobin.Experimental
BecaplerminPhenyl aminosalicylate may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BemiparinThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Bemiparin.Approved, Investigational
BenazeprilThe therapeutic efficacy of Benazepril can be decreased when used in combination with Phenyl aminosalicylate.Approved, Investigational
BeraprostThe risk or severity of adverse effects can be increased when Beraprost is combined with Phenyl aminosalicylate.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Betamethasone.Approved, Vet Approved
BivalirudinPhenyl aminosalicylate may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Brinzolamide.Approved
BromocriptinePhenyl aminosalicylate may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Budesonide.Approved
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Phenyl aminosalicylate.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Phenyl aminosalicylate.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Phenyl aminosalicylate.Investigational
CanagliflozinPhenyl aminosalicylate may increase the hypoglycemic activities of Canagliflozin.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Phenyl aminosalicylate.Experimental
CangrelorThe risk or severity of adverse effects can be increased when Cangrelor is combined with Phenyl aminosalicylate.Approved
CaplacizumabThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Caplacizumab.Investigational
CaptoprilThe therapeutic efficacy of Captopril can be decreased when used in combination with Phenyl aminosalicylate.Approved
Carbaspirin calciumPhenyl aminosalicylate may increase the anticoagulant activities of Carbaspirin calcium.Experimental, Investigational
CertoparinPhenyl aminosalicylate may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorpropamidePhenyl aminosalicylate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Phenyl aminosalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Ciclesonide.Approved, Investigational
CilazaprilThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Phenyl aminosalicylate.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Phenyl aminosalicylate.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Clocortolone.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Phenyl aminosalicylate.Approved
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Phenyl aminosalicylate.Experimental
ClorindionePhenyl aminosalicylate may increase the anticoagulant activities of Clorindione.Experimental
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Cortisone acetate.Approved, Investigational
Dabigatran etexilatePhenyl aminosalicylate may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinPhenyl aminosalicylate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidPhenyl aminosalicylate may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DapagliflozinPhenyl aminosalicylate may increase the hypoglycemic activities of Dapagliflozin.Approved
DarexabanPhenyl aminosalicylate may increase the anticoagulant activities of Darexaban.Investigational
DefibrotideThe risk or severity of adverse effects can be increased when Defibrotide is combined with Phenyl aminosalicylate.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Phenyl aminosalicylate.Investigational
DersalazineDersalazine may increase the anticoagulant activities of Phenyl aminosalicylate.Investigational
DesirudinPhenyl aminosalicylate may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Dexketoprofen.Approved, Investigational
DextranPhenyl aminosalicylate may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacThe therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Diclofenamide.Approved, Investigational
DicoumarolPhenyl aminosalicylate may increase the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Phenyl aminosalicylate.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Difluprednate.Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Phenyl aminosalicylate.Approved, Investigational
DiphenadionePhenyl aminosalicylate may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Phenyl aminosalicylate.Approved
DisopyramidePhenyl aminosalicylate may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Dorzolamide.Approved
Drotrecogin alfaThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DulaglutidePhenyl aminosalicylate may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
Edetic AcidPhenyl aminosalicylate may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanPhenyl aminosalicylate may increase the anticoagulant activities of Edoxaban.Approved
EmpagliflozinPhenyl aminosalicylate may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe therapeutic efficacy of Enalapril can be decreased when used in combination with Phenyl aminosalicylate.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Phenyl aminosalicylate.Approved
EnoxaparinPhenyl aminosalicylate may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineThe risk or severity of adverse effects can be increased when Epinastine is combined with Phenyl aminosalicylate.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when Eplivanserin is combined with Phenyl aminosalicylate.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Phenyl aminosalicylate.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Phenyl aminosalicylate.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Equilin.Approved
EstroneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Phenyl aminosalicylate.Approved, Investigational
EthoxzolamideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetatePhenyl aminosalicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
ExenatidePhenyl aminosalicylate may increase the hypoglycemic activities of Exenatide.Approved, Investigational
Ferulic acidPhenyl aminosalicylate may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fibrinolysin.Investigational
FluasteroneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fludrocortisone.Approved, Investigational
FluindionePhenyl aminosalicylate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Flunisolide.Approved, Investigational
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Flurandrenolide.Approved
FluticasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Fluticasone propionate.Approved
FondaparinuxPhenyl aminosalicylate may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure can be increased when Phenyl aminosalicylate is combined with Fosinopril.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Phenyl aminosalicylate.Approved, Vet Approved
GabexatePhenyl aminosalicylate may increase the anticoagulant activities of Gabexate.Investigational
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Phenyl aminosalicylate.Approved, Investigational, Nutraceutical
GliclazidePhenyl aminosalicylate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePhenyl aminosalicylate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePhenyl aminosalicylate may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GlyburidePhenyl aminosalicylate may increase the hypoglycemic activities of Glyburide.Approved
GuacetisalPhenyl aminosalicylate may increase the anticoagulant activities of Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HE3286The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with HE3286.Investigational
Hemoglobin crosfumarilPhenyl aminosalicylate may increase the anticoagulant activities of Hemoglobin crosfumaril.Experimental
HeparinPhenyl aminosalicylate may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Phenyl aminosalicylate.Approved, Investigational
HydrocortisoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Phenyl aminosalicylate.Approved, Investigational
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Phenyl aminosalicylate.Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Phenyl aminosalicylate.Approved, Investigational
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Phenyl aminosalicylate.Approved, Investigational, Nutraceutical
IdraparinuxPhenyl aminosalicylate may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Phenyl aminosalicylate.Approved, Investigational, Withdrawn
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Phenyl aminosalicylate.Investigational
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Phenyl aminosalicylate.Approved, Investigational
ImidaprilThe therapeutic efficacy of Imidapril can be decreased when used in combination with Phenyl aminosalicylate.Investigational
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Phenyl aminosalicylate.Investigational
Insulin AspartPhenyl aminosalicylate may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPhenyl aminosalicylate may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePhenyl aminosalicylate may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePhenyl aminosalicylate may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPhenyl aminosalicylate may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPhenyl aminosalicylate may increase the hypoglycemic activities of Insulin Lispro.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Istaroxime.Investigational
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Phenyl aminosalicylate.Investigational
KetorolacThe therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Ketorolac.Approved
LepirudinPhenyl aminosalicylate may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanPhenyl aminosalicylate may increase the anticoagulant activities of Letaxaban.Investigational
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Phenyl aminosalicylate.Experimental
LiraglutidePhenyl aminosalicylate may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Phenyl aminosalicylate.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Loteprednol.Approved
ME-609The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with ME-609.Investigational
MecaserminPhenyl aminosalicylate may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Medrysone.Approved
MelagatranPhenyl aminosalicylate may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Melengestrol.Vet Approved
MesalazineMesalazine may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
MetforminPhenyl aminosalicylate may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Methazolamide.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Phenyl aminosalicylate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Phenyl aminosalicylate.Approved
Methyl salicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Phenyl aminosalicylate is combined with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Methylprednisolone.Approved, Vet Approved
MifepristonePhenyl aminosalicylate may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPhenyl aminosalicylate may increase the hypoglycemic activities of Miglitol.Approved
MilrinoneThe risk or severity of adverse effects can be increased when Milrinone is combined with Phenyl aminosalicylate.Approved
MoexiprilThe therapeutic efficacy of Moexipril can be decreased when used in combination with Phenyl aminosalicylate.Approved
MometasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Mometasone.Approved, Vet Approved
NadroparinPhenyl aminosalicylate may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatPhenyl aminosalicylate may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Phenyl aminosalicylate.Investigational
NaproxenThe therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Naproxen.Approved, Vet Approved
NateglinidePhenyl aminosalicylate may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with NCX 1022.Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Phenyl aminosalicylate.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Phenyl aminosalicylate.Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Oleoyl-estrone.Investigational
OlsalazineOlsalazine may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
OmapatrilatThe therapeutic efficacy of Omapatrilat can be decreased when used in combination with Phenyl aminosalicylate.Investigational
OtamixabanPhenyl aminosalicylate may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Ozagrel.Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Paramethasone.Approved
ParnaparinThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Parnaparin.Approved, Investigational
Pentaerythritol TetranitratePhenyl aminosalicylate may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentamidinePhenyl aminosalicylate may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
Pentosan PolysulfatePhenyl aminosalicylate may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Phenyl aminosalicylate.Approved, Investigational
PerindoprilThe therapeutic efficacy of Perindopril can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenindionePhenyl aminosalicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonPhenyl aminosalicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Phenyl aminosalicylate.Experimental
PioglitazonePhenyl aminosalicylate may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Phenyl aminosalicylate.Approved
Potassium CitratePhenyl aminosalicylate may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Phenyl aminosalicylate.Approved, Investigational
PramlintidePhenyl aminosalicylate may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Prasterone sulfate.Investigational
PrasugrelThe risk or severity of adverse effects can be increased when Prasugrel is combined with Phenyl aminosalicylate.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Phenyl aminosalicylate.Approved, Investigational
Protein CPhenyl aminosalicylate may increase the anticoagulant activities of Protein C.Approved
Protein S humanPhenyl aminosalicylate may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydePhenyl aminosalicylate may increase the anticoagulant activities of Protocatechualdehyde.Approved
QuinaprilThe therapeutic efficacy of Quinapril can be decreased when used in combination with Phenyl aminosalicylate.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Phenyl aminosalicylate.Approved
QuininePhenyl aminosalicylate may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Phenyl aminosalicylate.Investigational
RamiprilThe therapeutic efficacy of Ramipril can be decreased when used in combination with Phenyl aminosalicylate.Approved
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Phenyl aminosalicylate.Investigational
RepaglinidePhenyl aminosalicylate may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Phenyl aminosalicylate.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Phenyl aminosalicylate.Approved, Experimental, Investigational
ReteplaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Reteplase.Approved, Investigational
ReviparinPhenyl aminosalicylate may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Phenyl aminosalicylate.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Rimexolone.Approved
RivaroxabanPhenyl aminosalicylate may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazonePhenyl aminosalicylate may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Salicylic acid is combined with Phenyl aminosalicylate.Approved, Investigational, Vet Approved
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Phenyl aminosalicylate.Investigational
SaruplaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Saruplase.Experimental
SaxagliptinPhenyl aminosalicylate may increase the hypoglycemic activities of Saxagliptin.Approved
SelexipagThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Selexipag.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Phenyl aminosalicylate.Approved, Vet Approved
SitagliptinPhenyl aminosalicylate may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
Sodium CitrateThe risk or severity of bleeding can be increased when Phenyl aminosalicylate is combined with Sodium Citrate.Approved, Investigational
SpiraprilThe therapeutic efficacy of Spirapril can be decreased when used in combination with Phenyl aminosalicylate.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Phenyl aminosalicylate.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Streptokinase.Approved, Investigational
SulfadiazinePhenyl aminosalicylate may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazolePhenyl aminosalicylate may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Sulfasalazine is combined with Phenyl aminosalicylate.Approved
SulfisoxazolePhenyl aminosalicylate may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Sulindac.Approved, Investigational
SulodexidePhenyl aminosalicylate may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SunitinibPhenyl aminosalicylate may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TemocaprilThe therapeutic efficacy of Temocapril can be decreased when used in combination with Phenyl aminosalicylate.Experimental, Investigational
TenecteplaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Tenecteplase.Approved
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Phenyl aminosalicylate.Investigational
TicagrelorThe risk or severity of adverse effects can be increased when Ticagrelor is combined with Phenyl aminosalicylate.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Phenyl aminosalicylate.Approved
TinzaparinThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Tinzaparin.Approved
TioclomarolPhenyl aminosalicylate may increase the anticoagulant activities of Tioclomarol.Experimental
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Phenyl aminosalicylate.Approved
TixocortolThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Tixocortol.Approved, Withdrawn
TolazamidePhenyl aminosalicylate may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolbutamidePhenyl aminosalicylate may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Phenyl aminosalicylate.Approved
TrandolaprilThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Phenyl aminosalicylate.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Phenyl aminosalicylate.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Phenyl aminosalicylate.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Phenyl aminosalicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Triamcinolone.Approved, Vet Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Phenyl aminosalicylate.Approved, Vet Approved
TriflusalThe risk or severity of adverse effects can be increased when Triflusal is combined with Phenyl aminosalicylate.Approved, Investigational
Trolamine salicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Phenyl aminosalicylate is combined with Trolamine salicylate.Approved
TroxerutinPhenyl aminosalicylate may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Ulobetasol.Approved
UrokinaseThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Urokinase.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Phenyl aminosalicylate.Approved, Investigational
VerapamilVerapamil may increase the anticoagulant activities of Phenyl aminosalicylate.Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Phenyl aminosalicylate.Approved
WarfarinPhenyl aminosalicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranPhenyl aminosalicylate may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Phenyl aminosalicylate.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
8290
ChEBI
114203
ChEMBL
CHEMBL1200868

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.173 mg/mLALOGPS
logP3.03ALOGPS
logP3.15ChemAxon
logS-3.1ALOGPS
pKa (Strongest Acidic)9.87ChemAxon
pKa (Strongest Basic)2.32ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area72.55 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity64.54 m3·mol-1ChemAxon
Polarizability23.52 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as depsides and depsidones. These are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure (depsidone).
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Depsides and depsidones
Sub Class
Not Available
Direct Parent
Depsides and depsidones
Alternative Parents
o-Hydroxybenzoic acid esters / Aminosalicylic acids and derivatives / Aminobenzoic acids and derivatives / Phenol esters / Phenoxy compounds / Benzoyl derivatives / Aniline and substituted anilines / m-Aminophenols / 1-hydroxy-4-unsubstituted benzenoids / 1-hydroxy-2-unsubstituted benzenoids
show 9 more
Substituents
Depside backbone / Aminosalicylic acid or derivatives / O-hydroxybenzoic acid ester / Aminobenzoic acid or derivatives / Benzoate ester / Phenol ester / Salicylic acid or derivatives / Benzoic acid or derivatives / M-aminophenol / Aniline or substituted anilines
show 23 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Drug created on September 14, 2010 10:21 / Updated on August 02, 2018 05:40